<DOC>
	<DOCNO>NCT00861328</DOCNO>
	<brief_summary>Treatment cancer often improve two drug use combination . In animal study , use combination ON 01910.Na ( new , unapproved drug ) irinotecan oxaliplatin ( two approve extensively use anti-cancer drug ) give good result tumor cell use single drug alone . In addition , use combination result increase side effect . This clinical trial determine high dose ON 01910.Na give safely combination either irinotecan oxaliplatin human patient .</brief_summary>
	<brief_title>Safety Study ON 01910.Na Combination With Irinotecan Oxaliplatin</brief_title>
	<detailed_description>This open-label , 2-arm , dose-escalation combination-therapy study patient advanced malignancy assign Investigator dose either irinotecan plus ON 01910.Na ( Group A ) , oxaliplatin plus ON 01910.Na ( Group B ) . The Investigator make assignment use clinical judgment , take consideration patient 's tumor type , UGT1A1 genotype applicable ( i.e. , patient consider treatment Group A test UGT1A1 genotype , already know , patient homozygous UGT1A1*28 allele exclude Group A ) , prior treatment , current clinical condition . Patients enrol 1 8 Cohorts ( 4 sequential Cohorts Group A 4 Group B ) 3 patient . Up 6 additional patient test MTD . Groups A B enroll proceed simultaneously .</detailed_description>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Male female patient ≥18 year age histologically cytologically confirm solid tumor metastatic progressive , standard therapy hold curative potential irinotecan oxaliplatin reasonable treatment option . Patients must evaluable disease , either measurable imaging informative tumor marker ( ) . Eastern Collaborative Oncology Group ( ECOG ) Performance Status ≤2 . Life expectancy &gt; 12 week . Any acute chronic adverse effect prior chemotherapy resolve &lt; Grade 2 determine CTCAE v3 criterion . Existing planned central venous access 2channel infusion catheter system . Laboratory value meet following criterion : Absolute neutrophil count ≥1,500 cells/µL ; Platelets ≥100,000 cells/µL ; Total bilirubin ≤1.5 time upper limit normal ; AST ( SGOT ) ≤2.5 time upper limit normal ; ALT ( SGPT ) ≤2.5 time upper limit normal ; Serum creatinine ≤1.5 mg/dL measure creatinine clearance ≥50 mL/min ; Negative βhCG test woman childbearing potential ( defined woman ≤50 year age history amenorrhea ≤12 month prior study entry ) . Patients primary liver cancer hepatic metastasis eligible enroll , provide meet follow : Total bilirubin ≤2 mg/dL ; AST ALT ≤5 time institutional upper limit normal ; Ascites , present , manageable diuretic agent alone . If history treat brain metastasis , must clinically stable ≥4 week prior enrollment . UGT1A1 genotype patient must know UGT1A1 genotype test must do patient consider treatment Group A . Women pregnant lactating . Patients chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study . Severe liver dysfunction ( ChildPugh Class C uncompensated Class B persistent encephalopathy , persistent ascites , prothrombin time &gt; 1.5 time upper limit normal ) present . Patients history esophageal bleeding exclude unless varix sclerosed band bleed episode occur prior 6 month . Contraindications , include know hypersensitivity , assign chemotherapy agent ( i.e. , irinotecan oxaliplatin ) . Prior receipt ON 01910.Na prior participation protocol . Use investigational agent within 4 week study enrollment . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement , determine Investigator . Patients homozygous UGT1A1*28 allele exclude participate Group A protocol . Patients ascites require active medical management include paracentesis , peripheral bilateral edema hyponatremia ( define serum sodium value &lt; 134 Meq/L ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>maximum tolerate dose</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>irinotecan</keyword>
	<keyword>ON 01910.Na</keyword>
</DOC>